The DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index.
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Open accessAbstract
Chimeric antigen receptor–modified (CAR-modified) T cells have shown promising therapeutic effects for hematological malignancies, yet limited and inconsistent efficacy against solid tumors. The refinement of CAR therapy requires an understanding of the optimal characteristics of the cellular products, including the appropriate composition of CD4 + and CD8 + subsets. Here, we investigated the differential antitumor effect of CD4 + and CD8 + CAR T cells targeting glioblastoma-associated (GBM-associated) antigen IL-13 receptor α2 (IL13Rα2). Upon stimulation with IL13Rα2 + GBM cells, the CD8 + CAR T cells exhibited robust short-term effector function but became rapidly exhausted. By comparison, the CD4 + CAR T cells persisted after tumor challenge and sustained their effector potency. Mixing with CD4 + CAR T cells failed to ameliorate the effector dysfunction of CD8 + CAR T cells, while surprisingly, CD4 + CAR T cell effector potency was impaired when coapplied with CD8 + T cells. In orthotopic GBM models, CD4 + outperformed CD8 + CAR T cells, especially for long-term antitumor response. Further, maintenance of the CD4 + subset was positively correlated with the recursive killing ability of CAR T cell products derived from GBM patients. These findings identify CD4 + CAR T cells as a highly potent and clinically important T cell subset for effective CAR therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, release of Th1 and Th2 cytokines by activated CD4+ T helper (Th) cells supports tumor cell killing by cytotoxic T cells, macrophages and granulocytes212.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cited by
Sorted by citations
Items 201–235 of 235
The Systemic Treatment of Glioma
Camargo, J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80047
EGFR as a potent CAR T target in Triple Negative Breast Cancer Brain MetastasesPreprint
Akhavan, D., Subham, S., Jeppson, J. D., Worcester, C. R., Schatmeyer, B. A., Zhao, J. V., Madan, R., Lakis, N. S., Kimler, B. F., McGuirk, J. P., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1828989/v1
Biology and status of chimeric antigen receptor-engineered T cell therapy
Murad, J. P., Park, A. K., & Priceman, S. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00018-5
Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2023) · doi:10.1158/2159-8290.c.6549389.v1
Self-citationWang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2023) · doi:10.1158/2159-8290.22540475.v1
Self-citationCheng, Q., Li, J., Feng, J., Li, Z., Ni, Y., Liu, L., Xia, L., Chai, Z., Zhuang, N., Xu, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3566958/v1
Additional file 6 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946374
Additional file 1 of Strategies to enhance CAR-T persistence
Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.21622536
The role of cellular persistence in CAR T cell therapy
Menkhoff, V. D., Bernhard, S., Michaelides, S., Stock, S., & Kobold, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00029-1
Targeting CD4+ T cell Exhaustion to Improve Future Immunotherapy Strategies
Simmons, T., & Levy, D. (2024) · Bulletin of Mathematical Biology · doi:10.1007/s11538-024-01389-8
Sauer, T., Chen, Q., Yao, H., Mao, L., Depke, D. A., Wang, L., Sedloev, D. N., Scheller, M., He, B., Liu, Y., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6283250/v1
CD4+ T cells in Antitumour Immunity
Bawden, E., & Gebhardt, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00187-3
Mapping CD4 + T Cell Landscapes in Glioblastoma Reveals Effectors and BystandersPreprint
Hill, C. M., Wang, A. Z., Maldonado, J., Johanns, T. M., Petti, A. A., & Dunn, G. P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.25.678410
Additional file 1 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946356
Additional file 4 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946368
Additional file 2 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946359
Additional file 5 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946371
Additional file 3 of Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Yang, Z., Li, L., Turkoz, A., Chen, P., Harari-Steinfeld, R., Bobbin, M. L., Stefanson, O., Choi, H., Pietrobon, V., Alphson, B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16946365
Gosmann, D., Russelli, L., Käsbauer, T., Bissenberger, S., Bassermann, F., Weber, W., D’Alessandria, C., & Krackhardt, A. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.23.693936
Freile, J. Á., Rockstein, L., Kloosterman, R., Corrales, M. G., Visser, N., Lourens, H. J., Frittmann, O., Dennebos, R., Smit, N. A. M., Setroikomo, A., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07701-5
Antigen Specificity and Cell Engineering Determine CAR T Cell Efficacy in Group 3 MedulloblastomaPreprint
Ward, M. B., Fouliard, J., Meehl, M., Dinh, D., Ibañez-Vega, J., Liu, J., Roussel, M. F., Yu, J., Gottschalk, S. M., & Krenciute, G. (2026) · Research Square · doi:10.21203/rs.3.rs-8863171/v1
γδ T cell-based immunotherapy against cytomegalovirus infection and glioblastoma : proof-of-concept
Marsères, G. (2022) · theses.fr (ABES) · doi:10.70675/0c3d3fbfzdda5z42cez801fzc60a0cccc3b9
Developing logic-gated CAR T cells for saferT-cell lymphoma therapy
Bourbon, E. (2025) · theses.fr (ABES) · doi:10.70675/11e2363dzeb1fz46bcza38dz6f6c7aa5545d
Le mimétique de SMAC GDC-0152 : un nouvel immunomodulateur dans les glioblastomes
Snacel-Fazy, E. (2023) · theses.fr (ABES) · doi:10.70675/7e5e377fzaaa9z4f1dzbde6z9586007f6c3d
Adaptive-like CAR-iPSC-CD4+ T cells outperform CD8+ counterparts in sustained ALL control
Qiang, G., Chaoqi, Z., 20994916, Chaoqi, Z., Bo, W., Shoichi, I., Akihiro, I., Minagawa, A., Tomoko, I., Yohei, K., et al. (2026) · Terrestrial Environment Research Center (University of Tsukuba)
Chen, Q., Sedloev, D., Yao, H., Mao, L.-H., Depke, D., Wang, L., Scheller, M., He, B.-L., Liu, Y., Unglaub, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.027
Liu, W., Ren, X., Zhang, Y., Yue, Q., Chen, X., Zhou, D., Li, X., Xin, Q., Kong, L., Wu, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04994-7
Advanced Materials for Biologics Delivery to Brain Tumors
Feng, Y., Cao, Y., Kavallaris, M., Janjua, T. I., & Popat, A. (2026) · Advanced Materials · doi:10.1002/adma.74760
Why CD4+ T cells matter in adoptive cell therapy for solid cancers
Jegatheeson, S., Scheffler, C. M., Bondt, M. D., Darcy, P., & Neeson, P. J. (2026) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2026.101615
Metadata
- Authors
- Wang, D., Aguilar, B., Starr, R., Alizadeh, D., Brito, A., Sarkissian, A., Ostberg, J. R., Forman, S. J., & Brown, C. E.
- Affiliations
- City Of Hope National Medical Center (US)
- CTI BioPharma (United Kingdom) (GB)
- Corresponding author
- Brown, Christine E.
- ORCID
- Venue
- JCI Insight
- Published
- 2018-05-17
- Volume
- 3
- Issue
- 10
- ISSN
- 2379-3708 (ISSN-L)
- PMC
- PMC6012522
- OpenAlex
- W2803369586
- Cited by
- 233
- References
- 75
- Citations by year
- 2026: 18 · 2025: 24 · 2024: 26 · 2023: 36 · 2022: 40 · 2021: 33 · 2020: 27 · 2019: 26 · 2018: 3
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- JCI Insight (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- California Institute for Regenerative Medicine (TR3-05641)
- National Cancer Institute (P30 CA33572)
- U.S. Food and Drug Administration (1R01FD005129-01)
- Gateway for Cancer Research (G-14-600)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- glioblastoma, chimeric antigen receptor T cells, CD4+ T cells, CD8+ T cells, IL-13 receptor alpha 2, CAR-T cell exhaustion, T cell persistence, T cell co-culture, antitumor immunity, solid tumor immunotherapy
- MeSH terms
- Glioblastoma, Humans, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
